UBS Group
CHRS icon

UBS Group’s Coherus Oncology CHRS Stock Holding History

UBS Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-29,900
Closed -$419K – 8000
2018
Q2 		$419K Buy
+29,900
New +$428K ﹤0.01% 4449

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

UBS Group's CHRS Position: Q2 2026 in Review

UBS Group increased its Coherus Oncology (CHRS) stake by 39% in Q2 2026, buying an estimated $348K and bringing the position to 760,358 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #5680.

UBS Group first reported a position in CHRS in Q4 2014 and has held it in 45 quarters since. The position peaked at $2.61M in Q4 2021. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • UBS Group held 760,358 shares of Coherus Oncology worth $1.06M as of Q2 2026.
  • UBS Group bought 213,149 Coherus Oncology shares in Q2 2026, an estimated $348K.
  • Coherus Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5680 holding.
  • UBS Group first reported a position in Coherus Oncology in Q4 2014 and has held it in 45 quarters since.
  • UBS Group's Coherus Oncology position peaked at $2.61M in Q4 2021.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.